|
1
|
American Cancer Society, . Global cancer
facts & figures. 4th. Atlanta: American Cancer Society;
2018
|
|
2
|
Mao Y, Yang D, He J and Krasna MJ:
Epidemiology of lung cancer. Surg Oncol Clin N Am. 25:439–445.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stankovic B, Bjørhovde HAK, Skarshaug R,
Aamodt H, Frafjord A, Müller E, Hammarström C, Beraki K, Bækkevold
ES, Woldbæk PR, et al: immune cell composition in human non-small
cell lung cancer. Front Immunol. 9:31012019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rong B and Yang S: Molecular mechanism and
targeted therapy of Hsp90 involved in lung cancer: New discoveries
and developments (Review). Int J Oncol. 52:321–336. 2018.PubMed/NCBI
|
|
5
|
Li S, Gao M, Li Z, Song L, Gao X, Han J,
Wang F, Chen Y, Li W, Yang J and Han X: Role of microRNAs in
metastasis of non-small cell lung cancer. Front Biosci (Landmark
Ed). 21:998–1005. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wood SL, Pernemalm M, Crosbie PA and
Whetton AD: The role of the tumor-microenvironment in lung
cancer-metastasis and its relationship to potential therapeutic
targets. Cancer Treat Rev. 40:558–566. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kumarswamy R, Mudduluru G, Ceppi P,
Muppala S, Kozlowski M, Niklinski J, Papotti M and Allgayer H:
MicroRNA-30a inhibits epithelial-to-mesenchymal transition by
targeting Snai1 and is downregulated in non-small cell lung cancer.
Int J Cancer. 130:2044–2053. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Iderzorig T, Kellen J, Osude C, Singh S,
Woodman JA, Garcia C and Puri N: Comparison of EMT mediated
tyrosine kinase inhibitor resistance in NSCLC. Biochem Biophys Res
Commun. 496:770–777. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li J, Wang Q, Wen R, Liang J, Zhong X,
Yang W, Su D and Tang J: MiR-138 inhibits cell proliferation and
reverses epithelial-mesenchymal transition in non-small cell lung
cancer cells by targeting GIT1 and SEMA4C. J Cell Mol Med.
19:2793–2805. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vishnoi A and Rani S: MiRNA biogenesis and
regulation of diseases: An overview. Methods Mol Biol. 1509:1–10.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhong K, Chen K, Han L and Li B:
MicroRNA-30b/c inhibits non-small cell lung cancer cell
proliferation by targeting Rab18. BMC Cancer. 14:7032014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen D, Guo W, Qiu Z, Wang Q, Li Y, Liang
L, Liu L, Huang S, Zhao Y and He X: MicroRNA-30d-5p inhibits tumour
cell proliferation and motility by directly targeting CCNE2 in
non-small cell lung cancer. Cancer Lett. 362:208–217. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhong Z, Xia Y, Wang P, Liu B and Chen Y:
Low expression of microRNA-30c promotes invasion by inducing
epithelial mesenchymal transition in non-small cell lung cancer.
Mol Med Rep. 10:2575–2579. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xu G, Cai J, Wang L, Jiang L, Huang J, Hu
R and Ding F: MicroRNA-30e-5p suppresses non-small cell lung cancer
tumorigenesis by regulating USP22-mediated Sirt1/JAK/STAT3
signaling. Exp Cell Res. 362:268–278. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li J, Sun W, Wei H, Wang X, Li H and Yi Z:
Expression of XB130 in human ductal breast cancer. Int J Clin Exp
Pathol. 8:5300–5308. 2015.PubMed/NCBI
|
|
16
|
Wang X, Wang R, Liu Z, Hao F, Huang H and
Guo W: XB130 expression in human osteosarcoma: A clinical and
experimental study. Int J Clin Exp Pathol. 8:2565–2573.
2015.PubMed/NCBI
|
|
17
|
Shiozaki A, Kosuga T, Ichikawa D, Komatsu
S, Fujiwara H, Okamoto K, Iitaka D, Nakashima S, Shimizu H,
Ishimoto T, et al: XB130 as an independent prognostic factor in
human esophageal squamous cell carcinoma. Ann Surg Oncol.
20:3140–3150. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen B, Liao M, Wei Q, Liu F, Zeng Q, Wang
W and Liu J, Hou J, Yu X and Liu J: XB130 is overexpressed in
prostate cancer and involved in cell growth and invasion.
Oncotarget. 7:59377–59387. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shi M, Zheng D, Sun L, Wang L, Lin L, Wu
Y, Zhou M and Liao W, Liao Y, Zuo Q and Liao W: XB130 promotes
proliferation and invasion of gastric cancer cells. J Transl Med.
12:12014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li GM, Liang CJ, Zhang DX, Zhang LJ, Wu JX
and Xu YC: XB130 knockdown inhibits the proliferation,
invasiveness, and metastasis of hepatocellular carcinoma cells and
sensitizes them to TRAIL-induced apoptosis. Chin Med J (Engl).
131:2320–2331. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shiozaki A, Lodyga M, Bai XH, Nadesalingam
J, Oyaizu T, Winer D, Asa SL, Keshavjee S and Liu M: XB130, a novel
adaptor protein, promotes thyroid tumor growth. Am J Pathol.
178:391–401. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xie T, Jiang C, Dai T, Xu R, Zhou X, Su X
and Zhao X: Knockdown of XB130 restrains cancer stem cell-like
phenotype through inhibition of Wnt/β-Catenin signaling in breast
cancer. Mol Carcinog. 58:1832–1845. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cho HR, Wang Y, Bai X, Xiang YY, Lu C,
Post A, Al Habeeb A and Liu M: XB130 deficiency enhances
carcinogen-induced skin tumorigenesis. Carcinogenesis.
40:1363–1375. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang Q, Yang G, Jiang Y, Luo M, Li C, Zhao
Y, Xie Y, Song K and Zhou J: XB130, regulated by miR-203, miR-219,
and miR-4782-3p, mediates the proliferation and metastasis of
non-small-cell lung cancer cells. Mol Carcinog. 59:557–568. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Takeshita H, Shiozaki A, Bai XH, Iitaka D,
Kim H, Yang BB, Keshavjee S and Liu M: XB130, a new adaptor
protein, regulates expression of tumor suppressive microRNAs in
cancer cells. PLoS One. 8:e590572013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fazilaty H, Rago L, Kass Youssef K, Ocaña
OH, Garcia-Asencio F, Arcas A, Galceran J and Nieto MA: A gene
regulatory network to control EMT programs in development and
disease. Nat Commun. 10:51152019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shukla V, Adiga D, Jishnu PV, Varghese VK,
Satyamoorthy K and Kabekkodu SP: Role of miRNA clusters in
epithelial to mesenchymal transition in cancer. Front Biosci (Elite
Ed). 12:48–78. 2020.PubMed/NCBI
|
|
28
|
Atambayeva S, Niyazova R, Ivashchenko A,
Pyrkova A, Pinsky I, Akimniyazova A and Labeit S: The binding sites
of miR-619-5p in the mRNAs of human and orthologous genes. BMC
Genomics. 18:4282017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kelly TJ, Suzuki HI, Zamudio JR, Suzuki M
and Sharp PA: Sequestration of microRNA-mediated target repression
by the Ago2-associated RNA-binding protein FAM120A. RNA.
25:1291–1297. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zheng Z, Reichel M, Deveson I, Wong G, Li
J and Millar AA: Target RNA secondary structure is a major
determinant of miR159 efficacy. Plant Physiol. 174:1764–1778. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bai XH, Cho HR, Moodley S and Liu M:
XB130-a novel adaptor protein: Gene, function, and roles in
tumorigenesis. Scientifica (Cairo). 2014:9030142014.PubMed/NCBI
|
|
32
|
Zhang J, Jiang X and Zhang J: Prognostic
significance of XB130 expression in surgically resected pancreatic
ductal adenocarcinoma. World J Surg Oncol. 12:492014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shiozaki A, Shen-Tu G, Bai X, Iitaka D, De
Falco V, Santoro M, Keshavjee S and Liu M: XB130 mediates cancer
cell proliferation and survival through multiple signaling events
downstream of Akt. PLoS One. 7:e436462012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yamanaka D, Akama T, Chida K, Minami S,
Ito K, Hakuno F and Takahashi S: Phosphatidylinositol
3-kinase-associated protein (PI3KAP)/XB130 crosslinks actin
filaments through its actin binding and multimerization properties
in vitro and enhances endocytosis in HEK293 cells. Front Endocrinol
(Lausanne). 7:892016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lodyga M, Xhi C, Anraku M, Liu N, Tsao M
and Liu M: P-080 Prognostic expression of a novel adaptor protein
XB130 in non-small-cell lung cancer. Lung Cancer. 49 (Suppl
2):S1352005. View Article : Google Scholar
|
|
36
|
Luan N, Wang Y and Liu X: Absent
expression of miR-30a promotes the growth of lung cancer cells by
targeting MEF2D. Oncol Lett. 16:1173–1179. 2018.PubMed/NCBI
|
|
37
|
Li G, Fang J, Wang Y, Wang H and Sun CC:
MiRNA-based therapeutic strategy in lung cancer. Curr Pharm Des.
23:6011–6018. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shiozaki A and Liu M: Roles of XB130, a
novel adaptor protein, in cancer. J Clin Bioinforma. 1:102011.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Xu J, Bai XH, Lodyga M, Han B, Xiao H,
Keshavjee S, Hu J, Zhang H, Yang BB and Liu M: XB130, a novel
adaptor protein for signal transduction. J Biol Chem.
282:16401–16412. 2007. View Article : Google Scholar : PubMed/NCBI
|
